MiRNA 126 as a New Predictor Biomarker in Venous Thromboembolism of Persistent Residual Vein Obstruction: A Review of the Literature Plus a Pilot Study

Pietro Rossetti; Matteo Goldoni; Vittorio Pengo; Rosanna Vescovini; Paola Mozzoni; Maria Ilaria Tassoni; Maria Lombardi; Pasquale Rubino; Gino Bernuzzi; Ignazio Verzicco; Cesare Manotti; Roberto Quintavalla

doi:10.1055/s-0041-1726341

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2021; 47(08): 982-991
DOI: 10.1055/s-0041-1726341

Review Article

MiRNA 126 as a New Predictor Biomarker in Venous Thromboembolism of Persistent Residual Vein Obstruction: A Review of the Literature Plus a Pilot Study

Pietro Rossetti

¹Department of Internal Medicine, Angiology and Coagulation Unit, University Hospital of Parma, Parma, Italy

,

Matteo Goldoni

²Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy

,

Vittorio Pengo

³Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy

,

Rosanna Vescovini

⁴Department of Clinical and Experimental Medicine, University Hospital of Parma, Parma, Italy

,

Paola Mozzoni

²Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy

,

Maria Ilaria Tassoni

¹Department of Internal Medicine, Angiology and Coagulation Unit, University Hospital of Parma, Parma, Italy

,

Maria Lombardi

¹Department of Internal Medicine, Angiology and Coagulation Unit, University Hospital of Parma, Parma, Italy

,

Pasquale Rubino

¹Department of Internal Medicine, Angiology and Coagulation Unit, University Hospital of Parma, Parma, Italy

,

Gino Bernuzzi

⁵Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy

,

Ignazio Verzicco

⁴Department of Clinical and Experimental Medicine, University Hospital of Parma, Parma, Italy

,

Cesare Manotti

¹Department of Internal Medicine, Angiology and Coagulation Unit, University Hospital of Parma, Parma, Italy

,

Roberto Quintavalla

¹Department of Internal Medicine, Angiology and Coagulation Unit, University Hospital of Parma, Parma, Italy

› Institutsangaben

Abstract

Venous thromboembolism (VTE) is the third most common cardiovascular disease. Interleukins (ILs) and micro-ribonucleic acids (miRNAs) have been proposed as molecules able to modulate endothelial inflammation and platelet hyperactivity. At present, no early biomarkers are available to predict the outcome of VTE. We investigated in a pilot study a selected number of miRNAs and ILs as prognostic VTE biomarkers and reviewed literature in this setting. Twenty-three patients (aged 18–65) with a new diagnosis of non-oncological VTE and free from chronic inflammatory diseases were enrolled. Twenty-three age- and sex-matched healthy blood donors were evaluated as control subjects. Serum miRNAs (MiRNA 126, 155, 17.92, 195), inflammatory cytokines (IL-6, tumor necrosis factor-α, IL-8), and lymphocyte subsets were evaluated in patients at enrolment (T0) and in controls. In VTE patients, clinical and instrumental follow-up were performed assessing residual vein obstruction, miRNA and ILs evaluation at 3 months' follow-up (T1). At T0, IL-8, activated T lymphocytes, Treg lymphocytes, and monocytes were higher in patients compared with healthy controls, as were miRNA 126 levels. Moreover, miRNA 126 and IL-6 were significantly increased at T0 compared with T1 evaluation in VTE patients. Higher levels of MiR126 at T0 correlated with a significant overall thrombotic residual at follow-up. In recent years an increasing number of studies (case–control studies, in vivo studies in animal models, in vitro studies) have suggested the potential role of miRNAs in modulating the cellular and biohumoral responses involved in VTE. In the frame of epidemiological evidence, this pilot study with a novel observational approach supports the notion that miRNA can be diagnostic biomarkers of VTE and first identifies miRNA 126 as a predictor of outcome, being associated with poor early recanalization.

Keywords

micro-RNA - immunothrombosis - deep vein thromboembolism - residual vein obstruction - prognostic biomarker

Volltext

Referenzen

References
1 Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest 2012; 122 (07) 2331-2336
2 von Brühl ML, Stark K, Steinhart A. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209 (04) 819-835
3 Fuchs TA, Brill A, Duerschmied D. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010; 107 (36) 15880-15885
4 Massberg S, Grahl L, von Bruehl ML. et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16 (08) 887-896
5 Semple JW, Italiano Jr JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11 (04) 264-274
6 Zapponi KC, Mazetto BM, Bittar LF. et al. Increased adhesive properties of neutrophils and inflammatory markers in venous thromboembolism patients with residual vein occlusion and high D-dimer levels. Thromb Res 2014; 133 (05) 736-742
7 Qin J, Liang H, Shi D. et al. A panel of microRNAs as a new biomarkers for the detection of deep vein thrombosis. J Thromb Thrombolysis 2015; 39 (02) 215-221
8 Mo J, Zhang D, Yang R. MicroRNA-195 regulates proliferation, migration, angiogenesis and autophagy of endothelial progenitor cells by targeting GABARAPL1. Biosci Rep 2016; 36 (05) e00396
9 Landskroner-Eiger S, Moneke I, Sessa WC. miRNAs as modulators of angiogenesis. Cold Spring Harb Perspect Med 2013; 3 (02) a006643
10 Fish JE, Santoro MM, Morton SU. et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15 (02) 272-284
11 Wang S, Aurora AB, Johnson BA. et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15 (02) 261-271
12 Wang XJ, Reyes JL, Chua NH, Gaasterland T. Prediction and identification of Arabidopsis thaliana microRNAs and their mRNA targets. Genome Biol 2004; 5 (09) R65
13 Kawasaki H, Taira K. MicroRNA-196 inhibits HOXB8 expression in myeloid differentiation of HL60 cells. Nucleic Acids Symp Ser (Oxf) 2004; (48) 211-212
14 Williams AE. Functional aspects of animal microRNAs. Cell Mol Life Sci 2008; 65 (04) 545-562
15 Meng Q, Wang W, Yu X. et al. Upregulation of microRNA-126 contributes to endothelial progenitor cell function in deep vein thrombosis via its target PIK3R2. J Cell Biochem 2015; 116 (08) 1613-1623
16 Dudda JC, Salaun B, Ji Y. et al. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 2013; 38 (04) 742-753
17 Romania P, Lulli V, Pelosi E, Biffoni M, Peschle C, Marziali G. MicroRNA 155 modulates megakaryopoiesis at progenitor and precursor level by targeting Ets-1 and Meis1 transcription factors. Br J Haematol 2008; 143 (04) 570-580
18 Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 2010; 42 (08) 1348-1354
19 He JF, Luo YM, Wan XH, Jiang D. Biogenesis of MiRNA-195 and its role in biogenesis, the cell cycle, and apoptosis. J Biochem Mol Toxicol 2011; 25 (06) 404-408
20 Fagnoni FF, Vescovini R, Passeri G. et al. Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. Blood 2000; 95 (09) 2860-2868
21 Prandoni P, Lensing AW, Prins MH. et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137 (12) 955-960
22 Prandoni P, Cogo A, Bernardi E. et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation 1993; 88 (4 Pt 1): 1730-1735
23 Siragusa S, Malato A, Saccullo G. et al. Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. Am J Hematol 2011; 86 (11) 914-917
24 Starikova I, Jamaly S, Sorrentino A. et al. Differential expression of plasma miRNAs in patients with unprovoked venous thromboembolism and healthy control individuals. Thromb Res 2015; 136 (03) 566-572
25 Ceppi M, Pereira PM, Dunand-Sauthier I. et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A 2009; 106 (08) 2735-2740
26 Nikolic I, Plate KH, Schmidt MHH. EGFL7 meets miRNA-126: an angiogenesis alliance. J Angiogenes Res 2010; 2 (01) 9
27 Chen L, Wang J, Wang B. et al. MiR-126 inhibits vascular endothelial cell apoptosis through targeting PI3K/Akt signaling. Ann Hematol 2016; 95 (03) 365-374
28 Pitzler L, Auler M, Probst K. et al. miR-126-3p promotes matrix-dependent perivascular cell attachment, migration and intercellular interaction. Stem Cells 2016; 34 (05) 1297-1309
29 Nosaka M, Ishida Y, Kimura A. et al. Detection of intrathrombotic endothelial progenitor cells and its application to thrombus age estimation in a murine deep vein thrombosis model. Int J Legal Med 2017; 131 (06) 1633-1638
30 Santo SD, Tepper OM, von Ballmoos MW. et al. Cell-based therapy facilitates venous thrombus resolution. Thromb Haemost 2009; 101 (03) 460-464
31 Moldovan NI, Asahara T. Role of blood mononuclear cells in recanalization and vascularization of thrombi: past, present, and future. Trends Cardiovasc Med 2003; 13 (07) 265-269
32 Morelli VM, Brækkan SK, Hansen JB. Role of microRNAs in venous thromboembolism. Int J Mol Sci 2020; 21 (07) E2602
33 Xiao J, Jing ZC, Ellinor PT. et al. MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J Transl Med 2011; 9: 159
34 Zhou X, Wen W, Shan X. et al. MiR-28-3p as a potential plasma marker in diagnosis of pulmonary embolism. Thromb Res 2016; 138: 91-95
35 Liu T, Kang J, Liu F. Plasma levels of microRNA-221 (miR-221) are increased in patients with acute pulmonary embolism. Med Sci Monit 2018; 24: 8621-8626
36 Wang X, Sundquist K, Svensson PJ. et al. Association of recurrent venous thromboembolism and circulating microRNAs. Clin Epigenetics 2019; 11 (01) 28
37 Jiang Z, Ma J, Wang Q, Wu F, Ping J, Ming L. Combination of circulating miRNA-320a/b and D-dimer improves diagnostic accuracy in deep vein thrombosis patients. Med Sci Monit 2018; 24: 2031-2037
38 Wang W, Li C, Li W. et al. MiR-150 enhances the motility of EPCs in vitro and promotes EPCs homing and thrombus resolving in vivo. Thromb Res 2014; 133 (04) 590-598
39 Sun S, Chai S, Zhang F, Lu L. Overexpressed microRNA-103a-3p inhibits acute lower-extremity deep venous thrombosis via inhibition of CXCL12. IUBMB Life 2020; 72 (03) 492-504
40 Wang Q, Ma J, Jiang Z, Wu F, Ping J, Ming L. Diagnostic value of circulating microRNA-27a/b in patients with acute pulmonary embolism. Int Angiol 2018; 37 (01) 19-25
41 Kirschner MB, van Zandwijk N, Reid G. Cell-free microRNAs: potential biomarkers in need of standardized reporting. Front Genet 2013; 4: 56
42 Xiang Q, Zhang HX, Wang Z. et al. The predictive value of circulating microRNAs for venous thromboembolism diagnosis: a systematic review and diagnostic meta-analysis. Thromb Res 2019; 181: 127-134
43 Du X, Hong L, Sun L. et al. miR-21 induces endothelial progenitor cells proliferation and angiogenesis via targeting FASLG and is a potential prognostic marker in deep venous thrombosis. J Transl Med 2019; 17 (01) 270
44 Zhang Y, Zhang Z, Wei R. et al. IL (Interleukin)-6 contributes to deep vein thrombosis and is negatively regulated by miR-338–5p. Arterioscler Thromb Vasc Biol 2020; 40 (02) 323-334